Literature DB >> 11585789

Active immunization in the United States: developments over the past decade.

P H Dennehy1.   

Abstract

The Centers for Disease Control and Prevention has identified immunization as the most important public health advance of the 20th century. The purpose of this article is to review the changes that have taken place in active immunization in the United States over the past decade. Since 1990, new vaccines have become available to prevent five infectious diseases: varicella, rotavirus, hepatitis A, Lyme disease, and Japanese encephalitis virus infection. Improved vaccines have been developed to prevent Haemophilus influenzae type b, pneumococcus, pertussis, rabies, and typhoid infections. Immunization strategies for the prevention of hepatitis B, measles, meningococcal infections, and poliomyelitis have changed as a result of the changing epidemiology of these diseases. Combination vaccines are being developed to facilitate the delivery of multiple antigens, and improved vaccines are under development for cholera, influenza, and meningococcal disease. Major advances in molecular biology have enabled scientists to devise new approaches to the development of vaccines against diseases ranging from respiratory viral to enteric bacterial infections that continue to plague the world's population.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11585789      PMCID: PMC89007          DOI: 10.1128/CMR.14.4.872-908.2001

Source DB:  PubMed          Journal:  Clin Microbiol Rev        ISSN: 0893-8512            Impact factor:   26.132


  335 in total

1.  Inactivated hepatitis A vaccine-induced antibodies: follow-up and estimates of long-term persistence.

Authors:  K Van Herck; P Van Damme
Journal:  J Med Virol       Date:  2001-01       Impact factor: 2.327

2.  Immunization against genital herpes with a vaccine virus that has defects in productive and latent infection.

Authors:  X J Da Costa; C A Jones; D M Knipe
Journal:  Proc Natl Acad Sci U S A       Date:  1999-06-08       Impact factor: 11.205

3.  Two-year comparative trial on the immunogenicity and adverse effects of purified chick embryo cell rabies vaccine for pre-exposure immunization.

Authors:  D W Dreesen; D B Fishbein; D T Kemp; J Brown
Journal:  Vaccine       Date:  1989-10       Impact factor: 3.641

Review 4.  Childhood immunization, vaccine-preventable diseases and infection with human immunodeficiency virus.

Authors:  I M Onorato; L E Markowitz; M J Oxtoby
Journal:  Pediatr Infect Dis J       Date:  1988-08       Impact factor: 2.129

5.  A double-blind trial of a new inactivated, trivalent, intra-nasal anti-influenza vaccine in general practice: relationship between immunogenicity and respiratory morbidity over the winter of 1997-98.

Authors:  A Kiderman; A Furst; B Stewart; E Greenbaum; A Morag; Z Zakay-Rones
Journal:  J Clin Virol       Date:  2001-02       Impact factor: 3.168

6.  A field trial with an improved Japanese encephalitis vaccine in a nonendemic area of the disease.

Authors:  M Kanamitsu; N Hashimoto; S Urasawa; M Katsurada; H Kimura
Journal:  Biken J       Date:  1970-12

Review 7.  Meningococcal vaccines. Current status and future possibilities.

Authors:  H Peltola
Journal:  Drugs       Date:  1998-03       Impact factor: 9.546

Review 8.  Possible approaches to develop vaccines against hepatitis A.

Authors:  E D'Hondt
Journal:  Vaccine       Date:  1992       Impact factor: 3.641

9.  Risk factors for systemic hypersensitivity reactions after booster vaccinations with human diploid cell rabies vaccine: a nationwide prospective study.

Authors:  D B Fishbein; K M Yenne; D W Dreesen; C F Teplis; N Mehta; D J Briggs
Journal:  Vaccine       Date:  1993-11       Impact factor: 3.641

10.  Colonization factors of enterotoxigenic Escherichia coli isolated from children in north India.

Authors:  H Sommerfelt; H Steinsland; H M Grewal; G I Viboud; N Bhandari; W Gaastra; A M Svennerholm; M K Bhan
Journal:  J Infect Dis       Date:  1996-10       Impact factor: 5.226

View more
  7 in total

1.  Congenital varicella syndrome.

Authors:  Lucien Corbeel
Journal:  Eur J Pediatr       Date:  2004-06       Impact factor: 3.183

2.  Seven great achievements in pediatric research in the past 40 y.

Authors:  Tina L Cheng; Nova Monteiro; Linda A DiMeglio; Alyna T Chien; Eric S Peeples; Elizabeth Raetz; Benjamin Scheindlin; Scott C Denne
Journal:  Pediatr Res       Date:  2016-09       Impact factor: 3.756

3.  Protective efficacy of a DNA influenza virus vaccine is markedly increased by the coadministration of a Schiff base-forming drug.

Authors:  Jehad Charo; Jan Alvar Lindencrona; Lena-Maria Carlson; Jorma Hinkula; Rolf Kiessling
Journal:  J Virol       Date:  2004-10       Impact factor: 5.103

4.  Of Mice and Men: On the Origin of XMRV.

Authors:  Antoinette Cornelia van der Kuyl; Marion Cornelissen; Ben Berkhout
Journal:  Front Microbiol       Date:  2011-01-17       Impact factor: 5.640

Review 5.  Vaccine chronicle in Japan.

Authors:  Tetsuo Nakayama
Journal:  J Infect Chemother       Date:  2013-07-09       Impact factor: 2.211

6.  Case report of congenital asplenia presenting with Haemophilus influenzae type a (Hia) sepsis: an emerging pediatric infection in Minnesota.

Authors:  Tiffany Albrecht; Kristina Poss; Satja Issaranggoon Na Ayuthaya; Lori Triden; Katherine L Schleiss; Mark R Schleiss
Journal:  BMC Infect Dis       Date:  2019-11-08       Impact factor: 3.090

7.  Production of inflammatory cytokines in response to diphtheria-pertussis-tetanus (DPT), haemophilus influenzae type b (Hib), and 7-valent pneumococcal (PCV7) vaccines.

Authors:  Yasuyo Kashiwagi; Akiko Miyata; Takuji Kumagai; Kouji Maehara; Eitarou Suzuki; Takao Nagai; Takao Ozaki; Naoko Nishimura; Kenji Okada; Hisashi Kawashima; Tetsuo Nakayama
Journal:  Hum Vaccin Immunother       Date:  2013-12-03       Impact factor: 3.452

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.